https://www.selleckchem.com/pr....oducts/aspirin-acety
There was no significant difference in the incidence of major adverse cardiac events (OR 0.71, CI 0.48-1.05, P = 0.54), myocardial re-infarction (OR 0.71, CI 0.48-1.05, P = 0.54), stroke (OR 0.61, CI 0.32-1.17, P = 0.14, and repeat PCI (OR 1.28, CI 0.91-1.78, P = 0.16). This meta-analysis shows lower long-term mortality and cardiac deaths in CTO-PCI group as compared to OMT driven by observational studies with no difference observed in randomized controlled trials. Further randomized trials are needed to confirm the
Like
Comment
Share
